Doctors reveal TERRIFYING new psychological side effects caused by Ozempic trends now
Blockbuster obesity drugs have transformed how we treat the condition - but doctors are warning they may cause potentially severe psychiatric effects.
Two new case reports reveal how two American patients became psychotic after taking semaglutide, the key ingredient in Ozempic and Wegovy.
One morbidly obese woman, 42, had been taking the drug for three weeks when she began suffering delusions that she was dead and attempted to strangle herself.
The symptoms went away after she came off the medication.
Another man, 72, who was described as 'highly functional', became manic after six weeks on the drug. He began cleaning the house compulsively and was convinced all his neighbors were dead.
Patients taking weight loss drugs such as semaglutide, the main ingredient in Wegovy and Ozempic, have reported behavior changes such as manic episodes as well as impulsive behavior leading to attempted suicides
The case reports were raised at a recent meeting of the American Psychiatric Association (APA).
A slew of reports just like these case have been reported around the world.
The doctors who treated the patients have called for patients given the new obesity drugs to be monitored once a week, even if they don't have a history of mental health issues.
For patients who do, they want healthcare providers to do a thorough background and family history check to gauge their risk.
Read More
Ozempic's links to suicide becoming 'more credible': FDA receives 265 reports of suicidal thoughts or despair linked to weight-loss drugs - even in people with NO history of depression
Zepbound and Wegovy include warnings on their labels about possible suicidal behavior, while Ozempic's lacks any warnings about psychological effects.
None of their labels include warnings or contraindications for people with bipolar disorder, warning them that they could see worsened depression or manic episodes.
A new KFF poll found that one in eight American adults have used the new obesity drugs, meaning millions could be susceptible to potentially severe psychiatric issues.
Dr Shahan Syed, from Bergen New Bridge Medical Center in New
